Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
about
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features.
P2860
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Updated analysis of CALGB (All ...... , double-blind, phase 3 trial.
@en
type
label
Updated analysis of CALGB (All ...... , double-blind, phase 3 trial.
@en
prefLabel
Updated analysis of CALGB (All ...... , double-blind, phase 3 trial.
@en
P2093
P2860
P50
P1476
Updated analysis of CALGB (All ...... , double-blind, phase 3 trial.
@en
P2093
Asad Bashey
Brian McClune
Cesar Rodriguez
Charles Linker
Chelsea Schultz
Chen Jiang
Craig C Hofmeister
Daniel J Weisdorf
David D Hurd
Edward A Stadtmauer
P2860
P356
10.1016/S2352-3026(17)30140-0
P577
2017-08-17T00:00:00Z